Thiazolidinediones on PPARγ: The roles in bone remodeling

Wei Wei, Yihong Wan

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations


Thiazolidinediones (TZDs) are synthetic PPAR (peroxisome proliferator-activated receptor gamma) agonists and a class of drugs for diabetes mellitus type 2 that can decrease blood sugar efficiently by enhancing insulin sensitivity. However, increased bone fracture risk in diabetic individuals treated with TZDs is one of the reported side effects. Recent studies show that TZDs such as rosiglitazone simultaneously inhibit osteoblast differentiation and activate osteoclast differentiation, leading to bone loss due to decreased bone formation and increased bone resorption. Furthermore, TZDs may activate PPAR in tissues other than bone, such as the hypothalamus- pituitary-gonad (HPG) axis to indirectly regulate bone mass. This paper will focus on current new developments that implicate potential mechanisms for how PPAR modulates skeletal homeostasis and how TZDs exert bone-loss side effects.

Original languageEnglish (US)
Article number867180
JournalPPAR Research
StatePublished - 2011

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology (medical)


Dive into the research topics of 'Thiazolidinediones on PPARγ: The roles in bone remodeling'. Together they form a unique fingerprint.

Cite this